Contact Us Billing Information
Factor_logo

MEDICAL BENEFITS BILLING PORTAL FOR PROVIDERS FOR CO-PAY ASSISTANCE, FREE TRIAL AND PATIENT ASSISTANCE


Co-Pay Assistance Program

If your patient’s primary payer drug claim is billed under medical benefits, you can request ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) and AlphaNine® SD (coagulation factor IX [human]) copay assistance using this portal. ​Eligible patients can receive up to $15,000 over 12 months to cover the deductible, copay, and/or coinsurance for ALPHANATE or AlphaNine SD.

Eligibility criteria for Co-Pay Assistance

Note: Nursing and supply costs that may be associated with the administration of the medication are not eligible for assistance through this program. For both medical and pharmacy benefits, claims must be received within 45 days of dispense date. For medical benefits only, EOBs must also be submitted within 180 days of the date the claim was submitted.


Free Trial Program

Free trial drug available to your patients who are new to ALPHANATE or AlphaNine SD and have not used a free trial offer for the product before. You can request up to 3 total doses with a maximum of 12,000 IUs through this Free Trial program.

Eligibility criteria for Free Trial


Patient Assistance Program

The Patient Assistance Program is for patients with no insurance coverage or lapsed coverage. This program offers free ALPHANATE or AlphaNine SD to uninsured who otherwise cannot afford their medications. Patients must meet financial and other program specific criteria to be eligible for assistance.

Eligibility criteria for Patient Assistance




This portal is administered by Medmonk for Factor for Health Program.


Important Safety Information: ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human])

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see ALPHANATE full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


Important Safety Information: AlphaNine® SD (coagulation factor IX [human])

AlphaNine SD is made from human plasma. Plasma products carry a risk of transmitting infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Incidences of thrombosis or disseminated intravascular coagulation (DIC) have been reported following administration of Factor IX Complex concentrates which contain high amounts of Factor II, VII and X. AlphaNine SD contains low, nontherapeutic levels of Factor II, VII and X.

Following administration in surgery patients and individuals with known liver disease, the physician should closely observe the patient for signs and symptoms of potential disseminated intravascular coagulation.

Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. The administration of plasma preparations may cause allergic reactions, mild chills, nausea or stinging at the infusion site.

Nephrotic syndrome has been reported following attempted immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of severe allergic reactions to Factor IX.

In order to minimize the possibility of thrombogenic complications, dosing guidelines should be strictly followed.

AlphaNine SD should not be administered at a rate exceeding 10 mL/ minute. Rapid administration may result in vasomotor reactions.

Please see AlphaNine full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.